A Look At The Career Of CEO Tony Petrello

Anthony Petrello, also known as Tony, began his career as a lawyer. From 179 to 1991 he worked for the New York law firm Baker & McKenzie, serving as the Managing Partner as of 1986. In 1991 he joined Nabor Industries, Ltd. as the company’s Chief Operating Officer. In 1992 he added the title of President. Today Tony Petrello is Nabor Industries Chairman of the Board, President, and Chief Executive Officer.

Nabor Industries is the world’s largest land-based driller. The company drills for oil, geothermal, and natural gas. Additionally, Nabor Industries provides rigs and technology to off-shore drilling companies around the globe. Before Tony Petrello joined the company it had been struggling, and in 1984 had declared bankruptcy. His leadership turned the company around and it has been profitable ever since. Due to his success, he has been greatly compensated, including earning $27.66 billion in 2015.

As the top executive at Nabor Industries, Tony Petrello oversees the company’s international operations. The company, operationally located in Houston, Texas, as oil field drilling rigs located across the United States, Canada, the Middle East, Africa, and the Far East. In just the United States, Nabor Industries operates 610 drilling operations, and 190 rigs in Canada.

Tony Petrello is also the director of another oil industry firm, Stewart & Stevenson, LLC. He is also the Director of MediaOnDemand.com and Texas Children’s Hospital, Inc. He became involved with Texas Children’s Hospital after his daughter, Carena, was born with cerebral palsy. Tony and his wife, Cynthia, have also donated $7 million to the Jan and Dan Duncan Neurological Research Institute which researches cerebral palsy and therapies that can help people who have the disease.

Learn more about Tony Petrello: http://www.thedailybeast.com/articles/2014/05/30/my-college-roommate-is-now-the-richest-ceo-in-america.html

Pulmonary Disease Suffers Can Begin To Breathe Easier

We are living in an age where new advances in medical treatment and cures for illnesses are being discovered and developed every day. Sharing in these spectacular events is the Lung Institute.

The Lung Institute is an advanced innovator of regenerative medicine, providing stem cell therapies to patients with lung disease. The advances of stem cell therapy are changing the lives of people with COPD, Chronic Bronchitis, Emphysema, Pulmonary Fibrosis, Bronchiectasis, Interstitial Lung Disease and Pneumoconiosis.

What is Stem Cell Therapy

Blood Venous Treatment is an alternative to Bone Marrow Therapy. According to the Baylor College of Medicine, the therapy is performed as an outpatient over a 2-3 day period. The abbreviated process is as follows:

  • The patients are evaluated to ensure they are a candidate for stem cell therapy.
  • The day of therapy treatment the patient is admitted to the hospital as an outpatient.
  • An IV is inserted into the patient, and the autologous, hematopoietic stem cells are harvested.
  • The blood is treated; stem cells are separated and immediately returned to the patient intravenously.
  • The IV returns the stem cells into the right ventricle of the heart. Within two heartbeats, the returned stem cells begin to reproduce, creating new healthy stem cells over and over again.
  • The blood leaves the heart and enters the pulmonary system where the stem cells continue to reproduce in masses. The cells remain for a short period in the pulmonary trap.
  • Then the stem cells are released into the bloodstream where these new cells travel throughout the body.

The process is repeated on day two, and if everything goes well the patient is released to go home, but return for follow-up care in a couple of weeks, then a few months to ensure the stem cell therapy was successful.

Additional Information

You are encouraged to call the Lung Institute at (800) 729-3065 to schedule a free consultation, or obtain additional information. The institute also has scheduled online webinars you can attend in the comfort of your home. You may want to visit their website https://lunginstitute.com/treatment/venous/ to read more about this new treatment for lung disease.

You can also check out the Lung Institute‘s social pages on YouTube and Twitter (https://twitter.com/lunginstitute?lang=en).

Securus Technologies Deflates the Bad Balloon

As one of the leading communications providers in the United States, Securus Technologies provides services to corrections institutions, law enforcement organizations and safety associations. They work with over 3,400 clients and over 1.2 million inmates and their immediate families.


The technology platform with Securus works with Andriod phones, iPhones, tablets, and regular landline configurations. There are several plans that are available from direct billing, collect calls, prepaid plans and inmate debit which has the inmate pay the phone charges.


It extraordinary how many companies just don’t take into account that their customers must be satisfied with the service they receive, or they won’t continue to stay with a company.


Unfortunately, a competitor, GTL recently was badmouthing Securus badly, to the point that it almost became slanderous. The direction that GTL was going with untrue information maintaining that their services and pricing structure put Securus to shame. In fact, there was absolutely nothing true about anything they said as if all of the information was coming from the Joker in Batman.


It got to the point where Securus had to do something about all of the nonsense, so they decided to put out a challenge to GTL. Each company would publicaly display the metrics of their equivalent servicing and pricing metrics to be compared by an independent and disinterested third party. The judgment would rest on his determination and his only.


Once the offer was made public, GTL was silent. Nothing at all. Then after a few weeks, GTL quietly notified Securus that they would not be willing to engage in the challenge.

The truth only hurts the dishonest, but it was the truth that won the day.